Advanced Therapies & Regenerative Medicine Speakers:

 
Ajan Reginald , Chief Executive Officer,  Celixir
Alain Vertès
, Managing Director,  NxR Biotechnologies
Alex Pemberton
, Programme Manager UKRMP,  Medical Research Council
André Choulika
, Chairman & Chief Executive Officer,  Cellectis
Andrea Piccin, Consultant Haematologist
, Haematology Dept & BMT Unit,  San Maurizio Regional Hospital Bolzano
Bob Harman
, CEO,  VetStem Biopharma, Inc.
Benjamin Shepherd
, Director, Therapeutics,  Organovo
Chaim Lebovits
, CEO,  Brainstorm Cell Therapeutics
Christoph Neyer
, ‎Director Business Development,  InGeneron GmbH
Claudia Mitchell
, CEO,  Universal Cells, Inc.
Damien Bates
, Chief Medical Officer & Head of Research,  SanBio
David Pettitt
, Research Associate, Centre for the Advancement of Sustainable Medical Innovation (CASMI), DPhil Candidate, Medical Sciences,  University of Oxford
Didier Caizergues
, Head of Regulatory Affairs Department,  Genethon
Diego Ardigò
, Project Lead,  Chiesi Group
Eduardo Bravo
, Managing Director and CEO,  TiGenix
Gerry Graham
, Head, Chemokine Research Group & Deputy Head of the Institute of Infection, Immunity and Inflammation,  University of Glasgow 
Giulia Detela
, Process Design Manager,  VivaBioCell S.p.A.
Ian Campbell
, Director for Health and Life Sciences,  Innovate UK 
James Miskin
, Chief Technical Officer,  Oxford BioMedica
James Noble
, CEO,  Adaptimmune
Jane Lebkowski
, ‎President of R&D,  Asterias Biotherapeutics
Jeff Abbey
, CEO,  Argos Therapeutics
Jeffrey Schaffer
, Director of Veterinary Professional Services,  VetStem
John Campbell
, Associate Director, Research, Development & Innovation, SNBTS,  National Science Laboratory
John Tchelingerian
, CEO, Promethera,  Biosciences
Katy Spink
, Chief Operating Officer,  Asterias Biotherapeutics
Kristin Comella
, Chief Science Officer,  US Stem Cell Inc.
Marc Turner
, Medical Director,  SNBTS
Margo Roberts
, CSO,  Kite Pharma
Mark Zimmerman
, Vice President, Business Development and Strategy,  ViaCyte
Mehis Pilv
, Cofounder and Managing Director,  GeneCode Ltd
Michael West
, CEO,  BioTime
Michele Lipucci
, CAT Full Member,  Patients’ representative, EMA
Nick Crabb
, Programme Director – Scientific Affairs,  NICE
Norio Nakatsuji, Founding Director
, Institute for Integrated Cell-Material Sciences (iCeMS),  Kyoto University, Kyoto, Japan
Ohad Karnieli
, Chair, Process and Product Development Subcommittee,  ISCT ; CEO & Co-Founder,  ATVIO 
Pascale V Guillot
, Head of the Cellular Reprogramming & Perinatal Therapy Team,  Institute for Women’s Health UCL
Paul Peter Tak
, Professor of Medicine, Rheumatology, Academic Medical Center,  University of Amsterdam AMC  (Senior Vice President of Research and Development Pipeline and Chief Immunology Officer,  GSK  & Board Member,  Galvani )
Peder Olofsson , Leader, Center for Bioelectronic Medicine, Department of Medicine,  Karolinska Institutet
Qasim Rafiq
, Senior Lecturer in Bioprocessing of Regenerative, Cellular and Gene Therapy,  UCL
Roger Smith
, Professor, Equine Orthopaedics,  Royal Veterinary College (RVC)
Stephen Badylak
, Professor, Department of Surgery, Deputy Director of the McGowan Institute for Regenerative Medicine (MIRM), & Director,  Center for Pre-Clinical Tissue Engineering within the Institute
Susan Solomon
, CEO and Co-Founder,  New York Stem Cell Foundation
Suzanne S. Farid
, Professor of Bioprocess Systems Engineering,  UCL
Todd McAllister
, Executive Director,  Amnion Foundation
Václav Procházka
, Deputy Director for Science & Research,  University Hospital Ostrava
Yen Choo
, CEO,  Progenitor Therapeutics
Zami Aberman
, Chairman & CEO,  Pluristem Therapeutics
Representative from Cellgenix
Representative from ThermoFisher
Representative from Cryoport
Representative from Terumo
 
 
 

AGENDA OVERVIEW:

 
 

DAY 1

OPENING KEYNOTES

PLATINUM SPONSOR ADDRESS

MORNING BREAK

PLENARY ROUNDTABLE SESSION

SPEED NETWORKING

LUNCH

Cell And Gene C-Level Forum

  • Regulation & reimbursement
  • Investment & funding strategies
  • Clinical development & product release

Clinical Development of ATMPs

  • Moving from phase II to phase III
AFTERNOON REFRESHMENTS

PLENARY KEYNOTE

POSTER ZONE & NETWORKING DRINKS  

 

DAY 2

OPENING KEYNOTES

PLATINUM SPONSOR ADDRESS

MORNING BREAK

Cell And Gene C-Level Forum

  • Regulation & reimbursement
  • Investment & funding strategies
  • Clinical development & product release

Clinical Development of ATMPs

  • Moving from phase II to phase III
LUNCH

Cell And Gene C-Level Forum

  • Regulation & reimbursement
  • Investment & funding strategies
  • Clinical development & product release

Future of Regen Med & Organ Regeneration

  • Starting materials isolation & selection of target cells, cell culture, activation and stimulation
  • Stem cell as a research tool
  • Stem cell transplantations
  • Tissue engineering and organ regeneration

AFTERNOON REFRESHMENTS

PLENARY KEYNOTE

POSTER ZONE & NETWORKING DRINKS  

 

 

DAY 3

Cell And Gene C-Level Forum

  • Using iPSCs as a disease model in drug-discovery
  • Characterisation and imaging assays
  • Identifying drug targets and mechanisms
  • Establishing technology platforms and assays that balance throughput and biological relevance

Future of Regen Med & Organ Regeneration

  • Starting materials isolation & selection of target cells, cell culture, activation and stimulation
  • Stem cell as a research tool
  • Stem cell transplantations
  • Tissue engineering and organ regeneration

LUNCH

CLOSING PLENARY: What to watch out for in 2018?

 

DOWNLOAD PROSPECTUS

To exhibit or sponsor call  Erica Baeta  on
+44(0) 207 092 1152  or email  erica.baeta@terrapinn.com         

 

 

The World Advanced Therapies & Regenerative Medicine Congress is two events: a world-class conference where hundreds of pharma, biotech and academia leaders from around the planet meet and a fantastic exhibition. To visit the show is free. There is, naturally, a registration fee to attend the conference. 

CONTACT US 
phone: +44 (0)207 092 1237 
email: 
  
jessica.robinson@terrapinn.com